Full-Time

Vice President

Chief of Staff

Posted on 8/18/2025

BlueRock Therapeutics

BlueRock Therapeutics

201-500 employees

Develops cellular therapies via gene platform

No salary listed

Cambridge, MA, USA

Hybrid

Category
Business & Strategy (3)
, ,
Requirements
  • Bachelor’s degree required; advanced degree (PhD or MD) strongly preferred
  • 12+ years in the pharmaceutical or biotechnology industry, with broad experience in strategic roles and a strong understanding of clinical development
  • Deep understanding of clinical development processes, including operations, governance, and execution
  • Proven experience leading cross-functional strategic and organizational initiatives in a global, matrixed environment
  • Demonstrated experience in strategic corporate planning with strong financial planning acumen
  • Demonstrated success in driving organizational development, change management, and performance improvement initiatives
  • Strong project management and prioritization skills with the ability to manage multiple workstreams across stakeholders
  • Excellent communication skills—written, verbal, and visual—with experience developing materials for senior and executive audiences
  • High emotional intelligence, cultural awareness, and the ability to build trusted relationships across teams and geographies
  • Strong leadership presence and the ability to influence without formal authority
  • Comfortable navigating ambiguity, complexity, and high-stakes environments
Responsibilities
  • Provide timely strategic advice and partnership to CEO through collaboration with the Executive Committee, board members, key stakeholders, internal project leaders and Bayer colleagues.
  • Lead role in preparation of agenda and slide preparation for all Board meetings and key external meetings.
  • Partner with the CEO and Executive Committee with corporate calendar management, assistance in corporate governance agenda builds, timely decision making, and partner with PRC and SBDC.
  • Lead cross-functional initiatives that improve organizational performance and support of BlueRock’s evolving strategy and needs, bringing together diverse perspectives and fostering a culture of trust, transparency, and innovation.
  • In collaboration with Finance, People and Culture, and Department leads, act as key strategic partner driving organizational performance through goal setting, strategic planning, headcount tracking, budget oversight for regular business reviews and annual planning exercises.
  • Facilitate effective and disciplined communication of the organization’s strategy and key messages at all levels – with the board, Bayer, and internally.
  • Drive clarity, accountability, and alignment across stakeholders—connecting teams to strategy and supporting collaboration, including participating in and engaging with our Leadership Forum.
  • Play a key role in defining Executive Committee’s strategic direction, driving the agenda and translating goals into operational plans.
  • Partner with the Executive Committee to optimize the current-state organization, design the future-state organization, and to identify and prioritize the changes needed to deliver the company’s mission and vision.
  • Identify and advise the Leadership Team on the implementation of new policies and procedures along with the implementation and design of new projects and change initiatives.
  • Plan and facilitate effective Executive Committee meetings and offsites, including agendas, facilitation, and action tracking.
Desired Qualifications
  • Advanced degree (PhD or MD) strongly preferred
BlueRock Therapeutics

BlueRock Therapeutics

View

BlueRock Therapeutics develops cellular therapies using a proprietary cell gene platform to direct how cells become therapeutic cells. The platform engineers cells for treatments in neurology, cardiology, and immunology, and the company works with healthcare providers, research institutions, and pharmaceutical partners to advance these therapies. Revenue comes from collaborations, licensing deals, and later potential product commercialization, rather than selling a single product outright. The goal is to build a portfolio of regenerative medicines and bring approved cellular therapies to patients through strategic partnerships and licensing.

Company Size

201-500

Company Stage

Acquired

Total Funding

$1.2B

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Bemdaneprocel shows positive safety through three years and RMAT designation accelerates Phase 3 entry.
  • OpCT-001 doses first patient in CLARICO Phase 1/2a trial on July 8, 2025, advancing vision restoration.
  • Oracle Cloud ERP deployment provides GxP-compliant manufacturing scale-up for clinical expansion.

What critics are saying

  • Aspen Neuroscience's sasineprocel Phase II data in 2026-2027 outpaces bemdaneprocel efficacy.
  • Immunogenicity triggers Phase III hold for bemdaneprocel in 18-36 months due to allogeneic cells.
  • Bayer divests BlueRock in 12-36 months amid portfolio rebalancing, halting funding.

What makes BlueRock Therapeutics unique

  • BlueRock pioneers iPSC-derived OpCT-001, first clinically tested photoreceptor therapy for primary photoreceptor diseases.
  • Bemdaneprocel uses hESC-derived dopaminergic neurons, differing from autologous iPSC competitors like Aspen's sasineprocel.
  • Bit.bio collaboration enables machine learning-driven iPSC Treg discovery for autoimmune therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
NexInfo Solutions, Inc.
Nov 26th, 2025
BlueRock Therapeutics Elevates Biopharmaceutical Agility with NexInfo and Oracle Cloud Applications

BlueRock Therapeutics elevates biopharmaceutical agility with NexInfo and Oracle Cloud Applications. BlueRock Therapeutics, a pioneering biotechnology company advancing cell-based therapies for neurological, cardiovascular, and immune disorders, recognized the urgent need to eliminate system fragmentation and build an integrated digital backbone to support its rapidly growing operations across R&D, manufacturing, supply chain, and finance. As a high-growth therapeutic developer with complex batch-based production, stringent regulatory oversight, and multi-site supply chain operations, BlueRock faced increasing challenges in managing material flow, production planning, quality control, and financial visibility using disconnected legacy tools. Manual workflows slowed operational efficiency, hindered compliance readiness, and reduced the organization's ability to scale with confidence. To accelerate its transformation and future-proof its operations, BlueRock partnered with NexInfo - an Oracle Cloud implementation leader - to deploy a comprehensive Oracle Cloud ERP and Supply Chain suite. The initiative aimed to create a unified, intelligent, and GxP-compliant digital ecosystem enabling real-time visibility, automated controls, and streamlined manufacturing and supply chain execution. About BlueRock Therapeutics BlueRock Therapeutics is a leading developer of regenerative cell therapies designed to restore human function and improve quality of life for patients with severe neurological, cardiac, and immunological conditions. With a mission to unlock the power of cell engineering, the company operates sophisticated manufacturing and research environments that demand precision, traceability, and end-to-end operational transparency. Replaced System: Coupa Oracle Cloud Modules Implemented: Supply Chain Planning, Procurement, Inventory Management, Manufacturing, Quality Management, Sales Order Management, Accounts Payable, Cash Management Deployment Region: North America Industry: Biotechnology & Biopharmaceuticals As BlueRock scaled production and expanded its clinical and commercial operations, legacy systems and manual processes created operational bottlenecks and limited the company's ability to maintain full visibility across the product lifecycle. * Fragmented Supply Chain Visibility: Disconnected systems hindered planning accuracy and material readiness. * Manual Procurement Workflows: Limited spend control and delayed supplier approvals affected sourcing efficiency. * Inefficient Inventory Tracking: Lack of real-time, compliant traceability across materials and batches. * Complex Manufacturing Processes: Manual batch execution and scheduling slowed throughput. * Limited Order-to-Cash Visibility: Disjointed order management impacted fulfillment and revenue timelines. * Decentralized Financial Operations: Manual AP and cash workflows delayed payments and constrained cash visibility. Collectively, these challenges hindered BlueRock's ability to operate with efficiency, precision, and regulatory confidence. Partnering with NexInfo: Building a Modern, Intelligent Biotech Enterprise With over 70% of biotechnology firms citing system fragmentation as a barrier to scale, the need for a unified digital backbone has never been clearer. Recognizing the need for a scalable and compliant system landscape, BlueRock partnered with NexInfo to redesign its enterprise architecture using Oracle Cloud Applications. NexInfo brought deep expertise in biopharmaceutical operations, GxP-aligned deployments, and cloud-enabled supply chain modernization. Together, they created a fully integrated, automated, and insight-driven platform supporting the complexity of advanced therapeutics manufacturing. The Solution: An Integrated Oracle Cloud Digital Backbone NexInfo implemented an end-to-end suite of Oracle Cloud modules to digitize, unify, and automate BlueRock's core operations. Unified demand - supply forecasting and improved material availability. Centralized sourcing, automated approvals, and improved supplier collaboration. Real-time visibility with lot and serial traceability across all sites. Standardized batch processes, automated shop-floor data capture, and optimized capacity planning. Integrated digital inspections, non-conformance management, and complete GxP traceability. Streamlined order-to-cash lifecycle integrated with inventory and manufacturing. Automated invoice processing and real-time cash visibility. BlueRock's transformation delivered measurable gains across the organization: * End-to-end supply chain visibility for proactive planning. * Centralized and compliant procurement operations across departments. * Optimized inventory and material traceability supporting FDA audits. * Digitally powered manufacturing with higher throughput. * Integrated quality controls ensuring full GxP compliance. * Stronger financial governance with automated AP and improved cash control. * Data-driven operational insights enabling faster decision-making. * Unified supply chain, manufacturing, and financial visibility * Automated procurement, fulfillment, and batch execution BlueRock's journey sets a benchmark for how advanced therapeutics organizations can unlock agility, compliance, and operational excellence through modern cloud technologies. About NexInfo NexInfo is a global Oracle Cloud consulting and implementation partner specializing in supply chain, ERP, manufacturing, and financial transformation. With over two decades of experience across life sciences, biotech, healthcare, manufacturing, and high-tech industries, NexInfo delivers: * Deep expertise in biopharma supply chain and manufacturing * World-class program governance and risk management NexInfo's global team of cloud architects, domain experts, and regulatory specialists enables organizations to accelerate digital transformation while ensuring operational continuity, compliance, and scalability. NexInfo's experts are available to assist with Oracle Cloud assessments, implementation planning, or end-to-end digital transformation support tailored to your industry. Accelerate business operations. Greater flexibility at a lower cost, speak with NexInfo Solutions, Inc. today!

Labiotech.eu
May 14th, 2025
The Stem Cell Race For Parkinson’S Disease: Recent Studies Show Significant Promise

Newsletter Signup - Under Article / In Page"*" indicates required fields Parkinson’s disease is an extremely complex condition to treat. Although there are medications available that can help relieve symptoms, there are still no approved therapies that slow down the progression of the underlying disease. But the biotech industry has not given up on finding new types of treatments that could potentially change the outcome for people suffering from the debilitating condition, and recent news of positive early-stage results for stem cell therapies has produced new hope for Parkinson’s patients.What are the causes of Parkinson’s disease and current therapeutic approaches?Although the underlying cause of Parkinson’s is unknown, scientists do know that the disease results from a loss of neurons in the substantia nigra region of the brain that make the chemical dopamine, which plays a crucial role in the brain’s reward system, influencing feelings of pleasure, motivation, and movement, as well as impacting mood, attention, learning, and memory. The loss of these neurons subsequently causes dopamine levels to plummet, which is ultimately the driving force behind why patients eventually experience such troublesome symptoms – these generally occur when around 80% of neurons have failed.Right now, the main treatment for Parkinson’s aims to increase the levels of dopamine in the brain. The drug levodopa is considered to be the most effective option, and is often combined with other medications to enhance its effectiveness and reduce side effects. However, not all patients respond to these drugs, and in some cases, doctors even perform surgery to run electrodes deep into the brain to help alleviate tremors and other symptoms.How can stem cell therapy treat Parkinson’s?But what if Parkinson’s could be treated directly at its source by actually restoring the lost neurons?That is exactly what stem cell therapies aim to do

FUJIFILM Cellular Dynamics
Sep 3rd, 2024
Fujifilm Congratulates BlueRock Therapeutics for Receiving FDA Clearance of its IND Application for its iPSC-derived Cell Therapy Candidate

OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.

BioInformant Worldwide, L.L.C.
Jun 12th, 2024
iPSC Applications in Cell Therapy, Drug Discovery, and Beyond

Since May 2021, BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics have had an R&D alliance to develop allogeneic iPSC-derived cell therapies for ocular diseases.

Bionews, Inc.
Jun 3rd, 2024
Cell therapy bemdaneprocel gets FDA RMAT status

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson's disease.

INACTIVE